Translational progress and bottlenecks in neurotransmitter-cancer research [2000–2025]: an integrated bibliometric and interventional trial analysis
Authors:
- Ming ZhangMZMing Zhang
- Weihao SunWSWeihao Sun
- Yizhao MaYMYizhao Ma
- Jialin C. ZhengJZJialin C. Zheng
- Qihui WuQWQihui Wu
- Ge GaoGGGe Gao
Open Access
- 1 April 2026
- journal article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (4) , 250
Abstract
Background: Neurotransmitter signaling influences cancer initiation, progression, and therapy response. We systematically characterized the field’s intellectual structure, thematic evolution, and translational trajectory. Methods: We analyzed 2,823 Web of Science articles [2000–2025] with CiteSpace and Bibliometrix, and reviewed 76 interventional trials from ClinicalTrials.gov to assess translational activity, drug-class distribution, and trial design trends. Results: Annual output nearly tripled, with >50% of papers published after 2020. The US led productivity (26.2%) and impact; China showed rapid output growth (18.1%). Oncology trials with tumor efficacy endpoints were dominated by β-adrenergic antagonists (33%), histone deacetylase (HDAC) inhibitors (16%), selective serotonin reuptake inhibitors (SSRIs) (22%), and dopamine modulators (13%). Since 2018, immunotherapy combinations increased (8 trials). Trials were skewed toward early-phase, and trial design heterogeneity and limited biomarker integration were common. Translational linkage was limited: only 4.5% of publications connected to identifiable trials. The neurotransmitter-immune axis emerged as a central translational theme. Conclusions: Neurotransmitter-cancer research has expanded rapidly but shows substantial translational attrition. Findings support continued evaluation of β-blockers in late-phase trials, prioritized testing of SSRI-immunotherapy combinations, and exploration of underrepresented GABAergic and cholinergic pathways. We recommend harmonized preclinical-to-clinical pipelines and accelerated biomarker development to improve translation. This evidence-based map can guide targeted translational strategies in neurotransmitter-directed oncology and precision oncology.Keywords
This publication has 32 references indexed in Scilit:
- The neuroscience of cancerNature, 2023
- Cancer neuroscience: State of the field, emerging directionsCell, 2023
- Understanding the role of dopamine in cancer: past, present and futureCarcinogenesis, 2022
- Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous SystemInternational Journal of Molecular Sciences, 2022
- The cholinergic anti-inflammatory pathway in humans: State-of-the-art review and future directionsNeuroscience & Biobehavioral Reviews, 2022
- Cancer catecholamine conundrumTrends in Cancer, 2022
- B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunityNature, 2021
- Catecholamines Mediate Psychologic Stress–Induced Cancer ProgressionCancer Research, 2021
- Neuro-Signals from Gut Microbiota: Perspectives for Brain GliomaCancers, 2021
- The cholinergic anti-inflammatory pathwayBrain, Behavior, and Immunity, 2005